Data to be shared during an ObesityWeek press conference include four of seven presentations supporting CONTRAVE and its utility in helping people lose weight BRENTWOOD, Tenn., Nov. 4, 2025 ...
Orexigen Therapeutics, Inc. (NASDAQ: OREX) may have jumped the gun in reporting that its anti-obesity drug Contrave offers unexpected benefits to cardiovascular patients. The Miami-based company ...
In January 2013, small biotechnology firm Orexigen was in the final stages of testing Contrave, a promising new pharmaceutical product for the treatment of obesity. At the time, Orexigen had no ...
Data to be shared during an ObesityWeek press conference includes four of seven data presentations supporting CONTRAVE and its utility in helping people lose weight BRENTWOOD, Tenn., Oct. 28, 2025 ...
Program ensures continued access to treatment for patients enrolled in the Federal Employee & Retirees Health Plan (FEP) BRENTWOOD, Tenn., Oct. 23, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results